COVID-19: A Healthcare Stakeholders Analysis in the United States and EU-5

COVID-19: Monitoring Impacts and Anticipating Trends to Limit Downturn and Optimize Rebound

Publications
Published on:
April 14, 2020
A Healthcare Stakeholders Analysis in the United States and EU-5 and a Practical Guide for Product Suppliers

The COVID-19 pandemic is having a disruptive effect on every corner of the healthcare industry, but its impact on individual stakeholders varies widely. Differences in exposure to COVID-19 patients, the relevance of product portfolios to the disease, and the level of preparedness for a pandemic have forced many across the industry to re-evaluate their strategies, quickly pivot to support urgent needs, and work to strengthen their position for the long-term rebound.

Alira Health’s team of strategists, scientists, doctors, and bankers continue to monitor the key trends and will share their perspective on underlying short, medium and long term implications to support the industry through this crisis and help continue to move healthcare forward during this time of uncertainty.

This 20-page report includes comprehensive analyses of the COVID-19 impact as of April 14, including:
  • An up-to-date digest of the impact COVID-19 is having on key healthcare stakeholders
  • Analysis of key trends and anticipated emerging needs
  • Business approaches for short-term reaction, and business model adaptations to help optimize for the rebound

 

For more information please contact our team:

Take our COVID-19 Impact Survey

Get started

 

Alira Health makes no representations or warranties, either expressed or implied, as to the accuracy of the information in this report. Alira Health has collected and compiled the presented information on a best effort basis under time and budget constraints. In no event will Alira Health be held liable for any direct, indirect, incidental or consequential damages arising out of the use of the information in this report.

Unless otherwise explicitly stated, all information is copyrighted by Alira Health, irrespective of whether a copyright symbol and statement is present. All trademarks are acknowledged.

Related news

Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Regulatory
Uncategorized April 13, 2022
U.S. and European Regulatory Strategies for Asian MedTech Startups
This webinar will focus on the U.S. FDA and EU MDR/IVDR regulatory pathways and strategies for medical device startups based in the Asia Pacific.
MedTech Regulatory
Publications April 8, 2022
Cheat Sheet: MDCG Guidance on Medical Device Classification
Assigning the proper class to a medical device (MD) is one of the most important activities carried out by a manufacturer. Read Alira Health's cheat sheet MDCG Guidance on Medical Device(...)
MedTech Regulatory
News April 5, 2022
Alira Health Strengthens Clinical Operations with the Acquisition of Sourcia
We acquired a full-service Contract Research Organization (CRO), Sourcia, that provides services for Phase I to Phase IV clinical trials with a focus on biotech, medical devices, and(...)
Clinical MedTech Patient Engagement Pharma Regulatory Research & Development
Publications March 31, 2022
The FDA’s Project Orbis Can Speed up the Delivery of Your New Oncology Drug to Global Markets
Are you developing an oncology drug? Project Orbis, a program coordinated by the U.S. Food and Drug Administration (FDA), allows you to register your product in several countries with(...)
Pharma Regulatory
Publications March 16, 2022
European Commission’s New Regulation Amending IVDR Transitional Provisions: What You Need to Know
The European Commission (EC) has published an amendment of the IVDR, delaying the transitional period for some IVDs. However, the IVDR Date of Application remains the same, so Alira(...)
Regulatory
Publications December 10, 2021
Leveraging Data Intelligence for Effective Opportunity Screening and Prioritization in Drug Discovery
Our biotech client needed an innovative, effective way to identify which binding sites and therapeutic indications they should target for the development of new therapeutic agents for(...)
Advanced Analytics Digital Health Pharma Research & Development
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.